Celsion Corporation

1.92+0.0200+1.05%Vol 52.93K1Y Perf 43.94%
Jun 27th, 2022 16:00 DELAYED
BID1.84 ASK1.99
Open1.91 Previous Close1.90
Pre-Market- After-Market1.99
 - -  0.07 3.65%
Target Price
27.00 
Analyst Rating
Strong Buy 1.00
Potential %
1.31K 
Finscreener Ranking
★★★★+     57.39
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
★★★+     53.32
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
★★★+     53.92
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
0.65 
Earnings Rating
Buy
Market Cap13.63M 
Earnings Date
11th Aug 2022
Alpha-0.03 Standard Deviation0.31
Beta2.28 

Today's Price Range

1.861.96

52W Range

1.8020.25

5 Year PE Ratio Range

-1.60-0.7000

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
0.00%
1 Month
-20.66%
3 Months
-63.22%
6 Months
240.79%
1 Year
43.94%
3 Years
5.49%
5 Years
-10.28%
10 Years
-98.97%

TickerPriceChg.Chg.%
CLSN1.920.02001.05
AAPL141.660.00000.00
GOOG2 332.45-38.3100-1.62
MSFT264.89-2.8100-1.05
XOM89.032.13002.45
WFC40.24-0.5200-1.28
JNJ182.12-0.1700-0.09
FB196.640.99000.51
GE66.71-0.2900-0.43
JPM116.38-0.9400-0.80
Financial StrengthValueIndustryS&P 500US Markets
6.20
6.60
0.12
0.14
-4.30
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
-
-4 375.90
-4 238.60
-4 284.80
-
RevenueValueIndustryS&P 500US Markets
500.00K
0.07
0.00
0.00
Earnings HistoryEstimateReportedSurprise %
Q01 2022-1.01-1.82-80.20
Q03 2021-1.20-0.9025.00
Q02 2021-1.20-0.9025.00
Q01 2021--1.35-
Q04 2020-1.95-0.7561.54
Q03 2020-1.95-2.55-30.77
Q02 2020-0.14-0.18-28.57
Q01 2020-0.17-0.20-17.65
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.9179.08Positive
9/2022 QR-0.9175.20Positive
12/2022 FY-4.38--
12/2023 FY-4.07--
Next Report Date11th Aug 2022
Estimated EPS Next Report-0.91
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume52.93K
Shares Outstanding7.10K
Shares Float7.06M
Trades Count298
Dollar Volume101.06K
Avg. Volume158.14K
Avg. Weekly Volume96.05K
Avg. Monthly Volume58.39K
Avg. Quarterly Volume319.98K

Celsion Corporation (NASDAQ: CLSN) stock closed at 1.92 per share at the end of the most recent trading day (a 1.05% change compared to the prior day closing price) with a volume of 52.93K shares and market capitalization of 13.63M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 29 people. Celsion Corporation CEO is Michael H. Tardugno.

The one-year performance of Celsion Corporation stock is 43.94%, while year-to-date (YTD) performance is 255.56%. CLSN stock has a five-year performance of -10.28%. Its 52-week range is between 1.8 and 20.25, which gives CLSN stock a 52-week price range ratio of 0.65%

Celsion Corporation currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 0.29, a price-to-sale (PS) ratio of 27.26, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -38.34%, a ROC of -36.04% and a ROE of -52.07%. The company’s profit margin is -%, its EBITDA margin is -4 238.60%, and its revenue ttm is $500.00 Thousand , which makes it $0.07 revenue per share.

Of the last four earnings reports from Celsion Corporation, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.91 for the next earnings report. Celsion Corporation’s next earnings report date is 11th Aug 2022.

The consensus rating of Wall Street analysts for Celsion Corporation is Strong Buy (1), with a target price of $27, which is +1 306.25% compared to the current price. The earnings rating for Celsion Corporation stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Celsion Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Celsion Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 36.96, ATR14 : 0.18, CCI20 : -64.00, Chaikin Money Flow : -0.24, MACD : -0.22, Money Flow Index : 30.05, ROC : -13.24, RSI : 34.93, STOCH (14,3) : 16.39, STOCH RSI : 0.71, UO : 38.64, Williams %R : -83.61), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Celsion Corporation in the last 12-months were: Frederick J. Fritz (Buy at a value of $47 222), Michael H. Tardugno (Buy at a value of $14 129)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (66.67 %)
1 (50.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
1 (33.33 %)
1 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Moderate Buy
1.67
Moderate Buy
2.00

Celsion Corporation

Celsion Corp is active in the biotechnology market. The company acts as a drug developer with product candidates like ThermoDox, a heat-activated liposomal encapsulation of doxorubicin. It is in Phase III clinical trial for the treatment of primary liver cancer and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer. Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers.

CEO: Michael H. Tardugno

Telephone: +1 609 896-9100

Address: 997 Lenox Drive, Lawrenceville 08648, NJ, US

Number of employees: 29

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

33%67%

Bearish Bullish

56%44%

Bearish Bullish

50%50%

Bearish Bullish

67%33%

TipRanks News for CLSN

Tue, 17 May 2022 10:15 GMT Analysts Offer Insights on Healthcare Companies: Celsion (CLSN), Altimmune (ALT) and Albireo Pharma (ALBO)

- TipRanks. All rights reserved.

Wed, 13 Apr 2022 10:15 GMT Analysts Top Healthcare Picks: Celsion (CLSN), Acer Therapeutics (ACER)

- TipRanks. All rights reserved.

News

Stocktwits